A phase II trial of to determine the anti-inflammatory effects of RPL 554 in healthy volunteers.
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2013
At a glance
- Drugs RPL 554 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors Verona Pharma
- 09 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 09 Sep 2013 Status changed from recruiting to completed.
- 10 Jul 2012 New trial record